By continuing browsing, you accept the use of cookies to improve the performance of this site and to offer you personalized services and content.

    Read more
    X
    Abivax
    • Allemand (DE)
    • English (UK)
    • Français (FR)
    • Home
    • Contact
    • Home
    • About us
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Technology
      Platform
      • Antiviral Platform
      • Immune Enhancer Platform
      • Polyclonal antibody Platform
    • Development
      Products
      • ABX464/HIV
      • ABX464/IBD
      • ABX544
      • ABX196
    • News & Events
      • Press Releases
      • Press Coverage
      • Forthcoming Events
    • Investors
      • Share Profile
      • Share Price
      • Financial Reports and Other Regulatory Information
      • Annual General Meeting
      • Investor presentations
      • Analysts following ABIVAX
      • Financial Agenda
      • Contact Us
    • Press Releases
    • Press Coverage
    • Forthcoming Events
    Home | News & Events | Press Releases
    • 20 May 2015

      ABIVAX plans IPO on the Euronext regulated market in Paris

      Read more Download as a pdf
    • 11 May 2015

      The Chairman of ABIVAX accompanies French President François Hollande during his trip to Cuba on May 11

      Read more Download as a pdf
    • 13 Apr 2015

      Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

      Read more Download as a pdf
    • 26 Feb 2015

      ABIVAX Recruits First Patient in a Pivotal Phase IIb/III clinical trial with ABX203, a novel immunotherapy against chronic hepatitis B

      Read more Download as a pdf
    • 2 Feb 2015

      TREATMENT OF THE FIRST HIV POSITIVE PATIENT IN ABIVAX’S PHASE IIA CLINICAL TRIAL WITH ABX464

      Read more Download as a pdf
    • 19 Dec 2014

      ABIVAX, A PRIVILEGED PARTNER OF THE CUBAN LIFE SCIENCE INDUSTRY, WELCOMES INITIATIVE TO RENEW RELATIONS BETWEEN THE USA AND CUBA

      Read more Download as a pdf

    Page 14 of 15

    • Start
    • Prev
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • Next
    • End

    Press contacts

    Caroline Carmagnol 

    abivax@alizerp.com

    + 33 6 64 18 99 59 or
    + 33 1 44 54 36 65

     Standard: +33 1 53 83 08 41

    • Home
    • About us
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Technology
      Platform
      • Antiviral Platform
      • Immune Enhancer Platform
      • Polyclonal antibody Platform
    • Development
      Products
      • ABX464/HIV
      • ABX464/IBD
      • ABX544
      • ABX196
    • News & Events
      • Press Releases
      • Press Coverage
      • Forthcoming Events
    • Investors
      • Share Profile
      • Share Price
      • Financial Reports and Other Regulatory Information
      • Annual General Meeting
      • Investor presentations
      • Analysts following ABIVAX
      • Financial Agenda
      • Contact Us
    © 2016 All rights reserved by ABIVAX - Legal Mentions - Stratégie et communication digitale : JLL CONSEIL

     


    Hello and welcome, do not hesitate to subscribe to receive our newsletter.

    Access to these materials is restricted in certain jurisdictions.

    The information included in this section is restricted due to applicable securities laws in your country of residence.

    The information in this section is, therefore, not available to persons located in your country of residence.

    Go to the Homepage


    The information contained on the pages that follow is restricted and is not for release, publication, or distribution in or into the Australia, Canada, Japan or the United States.

    The information contained herein is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States or to any U.S. person, as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”).

    None of the information contained on the pages that follow nor any copy thereof may be taken or transmitted in or into the United States or distributed, directly or indirectly, in or into the United States. Failure to comply with this directive may result in a violation of the Securities Act.